Our Promise: One pill, one bottle, one prescription, one refill, one dispensing fee, one co-pay, once-a-day.
Scientific Advisory Board
James D. Otvos, Ph.D.
Founder, Executive Vice President and Chief Scientific Officer, LipoScience Inc.
Dr. Otvos is a founder of LipoScience and has served as Chief Scientific Officer and a director since inception. He has also served as Executive Vice President since 1999.
He also currently serves as Adjunct Professor of Biochemistry at North Carolina State University. After receiving a Ph.D. in comparative biochemistry from the University of California-Berkeley in 1976 and postdoctoral training in molecular biophysics at Yale University, he joined the chemistry faculty at the University of Wisconsin- Milwaukee in 1980 and remained there until 1990. From 1990 to 2000, Dr. Otvos was Professor of Biochemistry at North Carolina State University.
DAVID BELL, M.D.
Professor of Medicine at the University of Alabama at Birmingham, School of Medicine
Dr. Bell is a leading authority on the prevention and treatment of type 2 diabetes.
During his distinguished career, he has contributed more than 180 articles to the medical literature. He is an active researcher and has served as Director of the Endocrine Clinical Research Program at the University of Alabama Birmingham.
Dr. Bell speaks nationally and internationally on the treatment of type 2 diabetes and its complications, and he is currently a member of the editorial boards of Endocrine Practice, Treatments in Endocrinology, Diabetes, and Obesity and Metabolism. He is a recipient of the Distinguished Clinician Award from the American College of Endocrinology for outstanding contribution as a master educator and clinician. Currently he is an investigator in the DREAM trials.
DREAM is an international, multi-center, randomized, double-blinded, placebo-controlled trial involving 4,000 participants at high risk for developing type II diabetes mellitus. Participants receive Ramipril (ACE-Inhibitor) or placebo and Rosiglitazone (a drug used to lower glucose in the blood) or placebo (One of the goals of the study is to establish epidemiological associations between cardiovascular disease and type II diabetes mellitus).
CARLOS M. FERRARIO, M.D., FACA, FACC
Professor of Physiology and Pharmacology Director, Hypertension and Vascular Research Center, Wake Forest University, Winston-Salem, NC
Dr. Carlos M. Ferrario graduated from the University of Buenos Aires Medical School in 1963.
After his postgraduate training in cardiology at the University of Geteborg and the Karolinska Institute in Sweden, he joined the Cleveland Clinic Foundation in 1966.
At the Cleveland Clinic Foundation, he was under the mentorship of Dr. Irvine H. Page, a pioneer in hypertension research. There, he developed his promising career and held numerous important positions such as the Chairman of Cardiovascular Research. He also pioneered research in the renin-angiotensin system, one of which led to his famous discovery of the function of angiotensin-(1-7) and ACE-2. In 1992, Dr. Ferrario assumed the directorship of the Hypertension and Vascular Disease Center of the Wake Forest University School of Medicine.
Dr. Ferrario has published over 500 papers, 3 books, and 70 book chapters. Just from that, one can easily imagine the degree of dedication to the advancement of cardiovascular research.